AbCellera Biologics Inc.

AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for medical needs. The company has developed a platform for advancing antibody drug programs, which it uses to address challenging targets like complex transmembrane proteins and novel modalities such as multispecifics and antibody-drug conjugates. While AbCellera previously used its platform for partner programs, it now focuses on building its own internal pipeline of drug assets. In 2025, AbCellera initiated clinical trials for its first two internal drug candidates. ABCL635, a potential non-hormonal medicine for moderate-to-severe vasomotor symptoms (VMS), or hot flashes, is in a Phase 2 clinical trial in Canada. ABCL575 is in a Phase 1 clinical trial in Canada as a potential medicine for atopic dermatitis and other inflammation and immunology (I&I) conditions. The company also nominated two additional development candidates, ABCL688 and ABCL386. AbCellera opened its clinical manufacturing facility in 2025, completing an investment in its integrated platform. As of December 31, 2025, AbCellera had approximately $700 million in available liquidity. The company's strategy is to create innovative medicines for patients, without focusing on specific indications.